DrugPatentWatch Database Preview

PYLERA Drug Profile

Pylera is a drug marketed by Allergan Sales Llc and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has thirty-two patent family members in twenty-four countries.

The generic ingredient in PYLERA is bismuth subcitrate potassium; metronidazole; tetracycline. There are twenty-one drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the bismuth subcitrate potassium; metronidazole; tetracycline profile page.

Ingredient-type	Nitroimidazoles Tetracyclines Bismuth
Drug Class	Nitroimidazole Antimicrobial Tetracycline-class Antimicrobial Bismuth

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Allergan Sales Llc	PYLERA	bismuth subcitrate potassium; metronidazole; tetracycline	CAPSULE;ORAL	050786-001	Sep 28, 2006		RX	Yes	Yes	➤ Sign Up	➤ Sign Up				➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Allergan Sales Llc	PYLERA	bismuth subcitrate potassium; metronidazole; tetracycline	CAPSULE;ORAL	050786-001	Sep 28, 2006	➤ Sign Up	➤ Sign Up
Allergan Sales Llc	PYLERA	bismuth subcitrate potassium; metronidazole; tetracycline	CAPSULE;ORAL	050786-001	Sep 28, 2006	➤ Sign Up	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration

Drugname	Dosage	Strength	RLD	Submissiondate
➤ Subscribe	Capsules	140 mg/125 mg/ 125 mg	➤ Subscribe	2014-08-12